A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Carfilzomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 04 Apr 2019 Status changed from active, no longer recruiting to completed.
- 05 Oct 2018 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.
- 05 Oct 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History